Adverum Biotechnologies (Adverum Biotechnologies) Gross Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Adverum Biotechnologies's Gross Profit for the three months ended in Mar. 2024 was $0.00 Mil. Adverum Biotechnologies's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Adverum Biotechnologies's Gross Margin % for the quarter that ended in Mar. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.

The historical rank and industry rank for Adverum Biotechnologies's Gross Margin % or its related term are showing as below:

ADVM's Gross Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: 59.74
* Ranked among companies with meaningful Gross Margin % only.

Adverum Biotechnologies had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Adverum Biotechnologies was 0.00% per year.

Adverum Biotechnologies Gross Margin % Historical Data

The historical data trend for Adverum Biotechnologies's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies Gross Margin % Chart

Adverum Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

Adverum Biotechnologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Adverum Biotechnologies's Gross Margin %

For the Biotechnology subindustry, Adverum Biotechnologies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adverum Biotechnologies's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's Gross Margin % falls into.

Adverum Biotechnologies Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Adverum Biotechnologies's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	3.6	/	3.6
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(3.6 - 0)	/	3.6
	=	N/A %

Adverum Biotechnologies's Gross Margin for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )	=	Gross Profit (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0	/	0
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0 - 0)	/	0
	=	N/A %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Adverum Biotechnologies (NAS:ADVM) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Adverum Biotechnologies had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Adverum Biotechnologies Gross Margin % Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adverum Biotechnologies (Adverum Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (NAS:ADVM) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

AVU:Germany

Address

100 Cardinal Way, Redwood CIty, CA, USA, 94063

Website

https://www.adverum.com

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Executives

C. David Nicholson,	director	103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Setareh Seyedkazemi	officer: Chief Development Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL DRIVE, REDWOOD CITY CA 94063
Linda M Rubinstein	officer: Chief Financial Officer	25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Peter Soparkar	officer: Chief Legal Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Brigit Riley	officer: Chief Scientific Officer	100 CARDINAL WAY, REDWOOD CITY CA 94063
Laurent Fischer	director, officer: CEO and Director	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Richard Beckman	officer: Chief Medical Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Nancy E Pecota	officer: Principal Accounting Officer	ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
John Rakow	officer: SVP, Genl Counsel, Acting CFO	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Rupert D'souza	officer: Chief Financial Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Soo Hong	director	C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063
Rabia Gurses Ozden	director	C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
James Paul Scopa	director	601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Julie Clark	officer: Chief Medical Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063